Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis
Anti-PD-1/PD-L1 inhibitors provide a survival advantage over conventional therapies for treatment of advanced or metastatic cancer. However, the factors determining which patients benefit the most from anti-PD-1/PD-L1 inhibitors are unknown, making treatment-related decisions difficult. We performed...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2020-02, Vol.10 (1), p.2083, Article 2083 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 2083 |
| container_title | Scientific reports |
| container_volume | 10 |
| creator | Sun, Leitao Zhang, Leyin Yu, Jieru Zhang, Yinan Pang, Xi Ma, Chenghao Shen, Minhe Ruan, Shanming Wasan, Harpreet S. Qiu, Shengliang |
| description | Anti-PD-1/PD-L1 inhibitors provide a survival advantage over conventional therapies for treatment of advanced or metastatic cancer. However, the factors determining which patients benefit the most from anti-PD-1/PD-L1 inhibitors are unknown, making treatment-related decisions difficult. We performed a systematic review and meta-analysis of acquired data to assess the efficacy and toxicity of anti-PD-1/PD-L1 inhibitors in advanced and metastatic cancer. A thorough search strategy was applied to identify randomised controlled trials (RCTs) in Pubmed, Embase, Cochrane, and major conferences. Studies meeting predefined selection criteria were selected, and two independent investigators performed data extraction; overall survival (OS), progression-free survival (PFS), and overall response rate were compared between anti-PD-1/PD-L1 inhibitors and control therapies. We calculated the pooled response rate and 95% CIs of all-grade and high-grade (≥3) adverse effects and evaluated the within-study heterogeneity using subgroup, sensitivity, and meta-regression analyses. In final, we included eligible 35 RCTs (21047 patients). The main estimated hazard ratios (HRs) for OS and PFS were 0.76 (0.71–0.82) and 0.81 (0.73–0.89) in a random-effects model. The anti-PD-1/PD-L1 inhibitor group had a significantly high risk for all-grade immune-related adverse events. Anti-PD-1/PD-L1 inhibitors were identified as a preferable treatment option for advanced or metastatic cancer patients who are male, aged |
| doi_str_mv | 10.1038/s41598-020-58674-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7005709</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2352321846</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-3524b0245746f870bf8a48e19c53aa68c5c48c254040a909e2acd29a2991909a3</originalsourceid><addsrcrecordid>eNp9UctuUzEQvUIgWpX-AAtkibWpn7k2CyQUnlKkdlHW1sTXblzdR7GdoPsffDCTpJSyqRf2PM6cmfFpmtecveNMmouiuLaGMsGoNotWUfWsORVMaSqkEM8f2SfNeSm3DI8WVnH7sjmRgkm0zGnze9mnMXnoSYgRXz8TGDtSIIY6kymiVxO9-kT5BV4rTtK4SetUp1xInDKpm0BqDlCHMNYDvtvB6ENHMDmECqVCTZ74fTC_J0DKXGoYDsEcdin8OjTcQymM0M8llVfNiwh9Cef371nz48vn6-U3urr8-n35cUW9VqxSqYVaM6F0qxbRtGwdDSgTuPVaAiyM114ZLxCrGFhmgwDfCQvCWo4uyLPmw5H3brseQudxhQy9u8tpgDy7CZL7PzOmjbuZdq7Fv2yZRYK39wR5-rkNpbrbaZtxi-IETicFN2qBKHFE-TyVkkN86MCZ24vpjmI6FNMdxHQKi948nu2h5K90CJBHQMHUeBPyv95P0P4BkgurTw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2352321846</pqid></control><display><type>article</type><title>Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis</title><source>MEDLINE</source><source>Nature Free</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature OA Free Journals</source><creator>Sun, Leitao ; Zhang, Leyin ; Yu, Jieru ; Zhang, Yinan ; Pang, Xi ; Ma, Chenghao ; Shen, Minhe ; Ruan, Shanming ; Wasan, Harpreet S. ; Qiu, Shengliang</creator><creatorcontrib>Sun, Leitao ; Zhang, Leyin ; Yu, Jieru ; Zhang, Yinan ; Pang, Xi ; Ma, Chenghao ; Shen, Minhe ; Ruan, Shanming ; Wasan, Harpreet S. ; Qiu, Shengliang</creatorcontrib><description>Anti-PD-1/PD-L1 inhibitors provide a survival advantage over conventional therapies for treatment of advanced or metastatic cancer. However, the factors determining which patients benefit the most from anti-PD-1/PD-L1 inhibitors are unknown, making treatment-related decisions difficult. We performed a systematic review and meta-analysis of acquired data to assess the efficacy and toxicity of anti-PD-1/PD-L1 inhibitors in advanced and metastatic cancer. A thorough search strategy was applied to identify randomised controlled trials (RCTs) in Pubmed, Embase, Cochrane, and major conferences. Studies meeting predefined selection criteria were selected, and two independent investigators performed data extraction; overall survival (OS), progression-free survival (PFS), and overall response rate were compared between anti-PD-1/PD-L1 inhibitors and control therapies. We calculated the pooled response rate and 95% CIs of all-grade and high-grade (≥3) adverse effects and evaluated the within-study heterogeneity using subgroup, sensitivity, and meta-regression analyses. In final, we included eligible 35 RCTs (21047 patients). The main estimated hazard ratios (HRs) for OS and PFS were 0.76 (0.71–0.82) and 0.81 (0.73–0.89) in a random-effects model. The anti-PD-1/PD-L1 inhibitor group had a significantly high risk for all-grade immune-related adverse events. Anti-PD-1/PD-L1 inhibitors were identified as a preferable treatment option for advanced or metastatic cancer patients who are male, aged < 65 years, current or former smokers, had no CNS or liver metastasis, had not EGFR mutation, and had high PD-L1 expression.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-020-58674-4</identifier><identifier>PMID: 32034198</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/308/409 ; 692/4028/67/1059/2325 ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; B7-H1 Antigen - antagonists & inhibitors ; Cancer ; Clinical trials ; Epidermal growth factor receptors ; Heterogeneity ; Humanities and Social Sciences ; Humans ; Inhibitors ; Meta-analysis ; Metastases ; Metastasis ; multidisciplinary ; Neoplasms - drug therapy ; Patients ; PD-1 protein ; PD-L1 protein ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Response rates ; Science ; Science (multidisciplinary) ; Survival ; Systematic review ; Toxicity ; Treatment Outcome</subject><ispartof>Scientific reports, 2020-02, Vol.10 (1), p.2083, Article 2083</ispartof><rights>The Author(s) 2020</rights><rights>This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c540t-3524b0245746f870bf8a48e19c53aa68c5c48c254040a909e2acd29a2991909a3</citedby><cites>FETCH-LOGICAL-c540t-3524b0245746f870bf8a48e19c53aa68c5c48c254040a909e2acd29a2991909a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005709/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005709/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,41096,42165,51551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32034198$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sun, Leitao</creatorcontrib><creatorcontrib>Zhang, Leyin</creatorcontrib><creatorcontrib>Yu, Jieru</creatorcontrib><creatorcontrib>Zhang, Yinan</creatorcontrib><creatorcontrib>Pang, Xi</creatorcontrib><creatorcontrib>Ma, Chenghao</creatorcontrib><creatorcontrib>Shen, Minhe</creatorcontrib><creatorcontrib>Ruan, Shanming</creatorcontrib><creatorcontrib>Wasan, Harpreet S.</creatorcontrib><creatorcontrib>Qiu, Shengliang</creatorcontrib><title>Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Anti-PD-1/PD-L1 inhibitors provide a survival advantage over conventional therapies for treatment of advanced or metastatic cancer. However, the factors determining which patients benefit the most from anti-PD-1/PD-L1 inhibitors are unknown, making treatment-related decisions difficult. We performed a systematic review and meta-analysis of acquired data to assess the efficacy and toxicity of anti-PD-1/PD-L1 inhibitors in advanced and metastatic cancer. A thorough search strategy was applied to identify randomised controlled trials (RCTs) in Pubmed, Embase, Cochrane, and major conferences. Studies meeting predefined selection criteria were selected, and two independent investigators performed data extraction; overall survival (OS), progression-free survival (PFS), and overall response rate were compared between anti-PD-1/PD-L1 inhibitors and control therapies. We calculated the pooled response rate and 95% CIs of all-grade and high-grade (≥3) adverse effects and evaluated the within-study heterogeneity using subgroup, sensitivity, and meta-regression analyses. In final, we included eligible 35 RCTs (21047 patients). The main estimated hazard ratios (HRs) for OS and PFS were 0.76 (0.71–0.82) and 0.81 (0.73–0.89) in a random-effects model. The anti-PD-1/PD-L1 inhibitor group had a significantly high risk for all-grade immune-related adverse events. Anti-PD-1/PD-L1 inhibitors were identified as a preferable treatment option for advanced or metastatic cancer patients who are male, aged < 65 years, current or former smokers, had no CNS or liver metastasis, had not EGFR mutation, and had high PD-L1 expression.</description><subject>692/308/409</subject><subject>692/4028/67/1059/2325</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>B7-H1 Antigen - antagonists & inhibitors</subject><subject>Cancer</subject><subject>Clinical trials</subject><subject>Epidermal growth factor receptors</subject><subject>Heterogeneity</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Inhibitors</subject><subject>Meta-analysis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>multidisciplinary</subject><subject>Neoplasms - drug therapy</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>PD-L1 protein</subject><subject>Programmed Cell Death 1 Receptor - antagonists & inhibitors</subject><subject>Response rates</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Survival</subject><subject>Systematic review</subject><subject>Toxicity</subject><subject>Treatment Outcome</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9UctuUzEQvUIgWpX-AAtkibWpn7k2CyQUnlKkdlHW1sTXblzdR7GdoPsffDCTpJSyqRf2PM6cmfFpmtecveNMmouiuLaGMsGoNotWUfWsORVMaSqkEM8f2SfNeSm3DI8WVnH7sjmRgkm0zGnze9mnMXnoSYgRXz8TGDtSIIY6kymiVxO9-kT5BV4rTtK4SetUp1xInDKpm0BqDlCHMNYDvtvB6ENHMDmECqVCTZ74fTC_J0DKXGoYDsEcdin8OjTcQymM0M8llVfNiwh9Cef371nz48vn6-U3urr8-n35cUW9VqxSqYVaM6F0qxbRtGwdDSgTuPVaAiyM114ZLxCrGFhmgwDfCQvCWo4uyLPmw5H3brseQudxhQy9u8tpgDy7CZL7PzOmjbuZdq7Fv2yZRYK39wR5-rkNpbrbaZtxi-IETicFN2qBKHFE-TyVkkN86MCZ24vpjmI6FNMdxHQKi948nu2h5K90CJBHQMHUeBPyv95P0P4BkgurTw</recordid><startdate>20200207</startdate><enddate>20200207</enddate><creator>Sun, Leitao</creator><creator>Zhang, Leyin</creator><creator>Yu, Jieru</creator><creator>Zhang, Yinan</creator><creator>Pang, Xi</creator><creator>Ma, Chenghao</creator><creator>Shen, Minhe</creator><creator>Ruan, Shanming</creator><creator>Wasan, Harpreet S.</creator><creator>Qiu, Shengliang</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20200207</creationdate><title>Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis</title><author>Sun, Leitao ; Zhang, Leyin ; Yu, Jieru ; Zhang, Yinan ; Pang, Xi ; Ma, Chenghao ; Shen, Minhe ; Ruan, Shanming ; Wasan, Harpreet S. ; Qiu, Shengliang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-3524b0245746f870bf8a48e19c53aa68c5c48c254040a909e2acd29a2991909a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>692/308/409</topic><topic>692/4028/67/1059/2325</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>B7-H1 Antigen - antagonists & inhibitors</topic><topic>Cancer</topic><topic>Clinical trials</topic><topic>Epidermal growth factor receptors</topic><topic>Heterogeneity</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Inhibitors</topic><topic>Meta-analysis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>multidisciplinary</topic><topic>Neoplasms - drug therapy</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>PD-L1 protein</topic><topic>Programmed Cell Death 1 Receptor - antagonists & inhibitors</topic><topic>Response rates</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Survival</topic><topic>Systematic review</topic><topic>Toxicity</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sun, Leitao</creatorcontrib><creatorcontrib>Zhang, Leyin</creatorcontrib><creatorcontrib>Yu, Jieru</creatorcontrib><creatorcontrib>Zhang, Yinan</creatorcontrib><creatorcontrib>Pang, Xi</creatorcontrib><creatorcontrib>Ma, Chenghao</creatorcontrib><creatorcontrib>Shen, Minhe</creatorcontrib><creatorcontrib>Ruan, Shanming</creatorcontrib><creatorcontrib>Wasan, Harpreet S.</creatorcontrib><creatorcontrib>Qiu, Shengliang</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sun, Leitao</au><au>Zhang, Leyin</au><au>Yu, Jieru</au><au>Zhang, Yinan</au><au>Pang, Xi</au><au>Ma, Chenghao</au><au>Shen, Minhe</au><au>Ruan, Shanming</au><au>Wasan, Harpreet S.</au><au>Qiu, Shengliang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2020-02-07</date><risdate>2020</risdate><volume>10</volume><issue>1</issue><spage>2083</spage><pages>2083-</pages><artnum>2083</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Anti-PD-1/PD-L1 inhibitors provide a survival advantage over conventional therapies for treatment of advanced or metastatic cancer. However, the factors determining which patients benefit the most from anti-PD-1/PD-L1 inhibitors are unknown, making treatment-related decisions difficult. We performed a systematic review and meta-analysis of acquired data to assess the efficacy and toxicity of anti-PD-1/PD-L1 inhibitors in advanced and metastatic cancer. A thorough search strategy was applied to identify randomised controlled trials (RCTs) in Pubmed, Embase, Cochrane, and major conferences. Studies meeting predefined selection criteria were selected, and two independent investigators performed data extraction; overall survival (OS), progression-free survival (PFS), and overall response rate were compared between anti-PD-1/PD-L1 inhibitors and control therapies. We calculated the pooled response rate and 95% CIs of all-grade and high-grade (≥3) adverse effects and evaluated the within-study heterogeneity using subgroup, sensitivity, and meta-regression analyses. In final, we included eligible 35 RCTs (21047 patients). The main estimated hazard ratios (HRs) for OS and PFS were 0.76 (0.71–0.82) and 0.81 (0.73–0.89) in a random-effects model. The anti-PD-1/PD-L1 inhibitor group had a significantly high risk for all-grade immune-related adverse events. Anti-PD-1/PD-L1 inhibitors were identified as a preferable treatment option for advanced or metastatic cancer patients who are male, aged < 65 years, current or former smokers, had no CNS or liver metastasis, had not EGFR mutation, and had high PD-L1 expression.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32034198</pmid><doi>10.1038/s41598-020-58674-4</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2020-02, Vol.10 (1), p.2083, Article 2083 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7005709 |
| source | MEDLINE; Nature Free; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry; Springer Nature OA Free Journals |
| subjects | 692/308/409 692/4028/67/1059/2325 Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use B7-H1 Antigen - antagonists & inhibitors Cancer Clinical trials Epidermal growth factor receptors Heterogeneity Humanities and Social Sciences Humans Inhibitors Meta-analysis Metastases Metastasis multidisciplinary Neoplasms - drug therapy Patients PD-1 protein PD-L1 protein Programmed Cell Death 1 Receptor - antagonists & inhibitors Response rates Science Science (multidisciplinary) Survival Systematic review Toxicity Treatment Outcome |
| title | Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T23%3A20%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20efficacy%20and%20safety%20of%20anti-PD-1/PD-L1%20inhibitors%20for%20the%20treatment%20of%20advanced%20or%20metastatic%20cancer:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=Scientific%20reports&rft.au=Sun,%20Leitao&rft.date=2020-02-07&rft.volume=10&rft.issue=1&rft.spage=2083&rft.pages=2083-&rft.artnum=2083&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-020-58674-4&rft_dat=%3Cproquest_pubme%3E2352321846%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2352321846&rft_id=info:pmid/32034198&rfr_iscdi=true |